1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
- 2022
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2020
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
- 2018
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
- 2017
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Correlation to FVIII : C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
(
- Contribution to journal › Article
- 2016
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
-
Mark
Future of haemophilia outcome assessment : Registries are key to optimized treatment
(
- Contribution to journal › Article